Heerspink HJL focused on the cardiovascular and renal effects, potential mechanisms, and clinical applications of SGLT2 inhibitors in the treatment of diabetes mellitus, especially in the kidney (Heerspink et al., 2016; Heerspink et al., 2017; Heerspink et al., 2019). The gene discussed is SLC5A2; the disease is diabetes mellitus.